As Drug Shortages Plague The U.S., Could India’s Strides Be Looking To Sell?
This article was originally published in PharmAsia News
Aided by an acute drug shortage in the U.S., Agila, the injectables business of Strides, has grown rapidly, sparking speculation of a buyout from a global bidder. PharmAsia News takes a closer look.
You may also be interested in...
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.